Powder: -20°C for 3 years | In solvent: -80°C for 1 year
GSK046 (iBET-BD2) is a potent, selective and orally active BD2 bromodomain inhibitor of the BET proteins(IC50s of 264 nM (BRD2 BD2), 98 nM (BRD3 BD2), 49 nM (BRD4 BD2) and 214 nM (BRDT BD2), respectively). It has immunomodulatory activity.
パッケージサイズ | 在庫状況 | 単価(税別) | |||
---|---|---|---|---|---|
サンプルについてお問い合わせ | |||||
1 mg | 在庫あり | ¥ 26,500 | |||
5 mg | 在庫あり | ¥ 57,000 | |||
10 mg | 在庫あり | ¥ 91,500 | |||
25 mg | 在庫あり | ¥ 152,500 | |||
50 mg | 在庫あり | ¥ 217,000 | |||
100 mg | 在庫あり | ¥ 294,000 | |||
1 mL * 10 mM (in DMSO) | 在庫あり | ¥ 62,500 |
説明 | GSK046 (iBET-BD2) is a potent, selective and orally active BD2 bromodomain inhibitor of the BET proteins(IC50s of 264 nM (BRD2 BD2), 98 nM (BRD3 BD2), 49 nM (BRD4 BD2) and 214 nM (BRDT BD2), respectively). It has immunomodulatory activity. |
ターゲット&IC50 | BRD4 BD2:49 nM (IC50), BRD3 BD2:98 nM (IC50), BRDT BD2:214 nM (IC50), BRD2 BD2:264 nM (IC50) |
In vivo | GSK046 (40 mg/kg/QD;?s.c. for 14 days) has immunomodulatory activity.?GSK046 exhibits Cmax (C57BL6 1589, C57B16 2993 ng/mL) and terminal elimination half-lives (C57BL6 1.8, C57B16 1.9 h) following oral administration (C57BL6 10, C57B16 40 mg/kg).?GSK046 exhibits Cmax (mouse 1589, rat 202 ng/mL) and terminal elimination half-lives (mouse 1.8, rat 1.4 h) following oral administration (mouse 10, rat 10 mg/kg)[1]. |
別名 | iBET-BD2 |
分子量 | 414.47 |
分子式 | C23H27FN2O4 |
CAS No. | 2474876-09-8 |
Powder: -20°C for 3 years | In solvent: -80°C for 1 year
DMSO: 83.33 mg/mL (201.05 mM), Sonication is recommended.
You can also refer to dose conversion for different animals. 詳細
bottom
Please see Inhibitor Handling Instructions for more frequently ask questions. Topics include: how to prepare stock solutions, how to store products, and cautions on cell-based assays & animal experiments, etc.
GSK046 2474876-09-8 Chromatin/Epigenetic Epigenetic Reader Domain GSK-046 BRDT BRD2 inhibit immuno-inflammation iBET-BD2 BRD4 GSK 046 Inhibitor BD2 BRD3 inhibitor